IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer.

摘要: Squamous cell carcinoma (SCC) of the head and neck (HN increased expression is associated with enhanced tumour invasion, resistance to chemotherapy decreased patient survival. Several approaches have been developed achieve EGFR blockade as an anticancer treatment strategy, including anti-EGFR monoclonal antibody (mAb), IMC-C225, which competitively binds extracellular receptor site prevent binding by natural ligands (EGF TGF-alpha). Preclinical studies evaluating this chimeric mAb in human cancer lines vitro xenografts vivo demonstrated its potent antitumour activity. The clinical efficacy IMC-C225 appears involve multiple mechanisms, inhibition cycle progression, induction apoptosis, anti-angiogenesis, metastasis ability enhance response radiation therapy. Phase I combined or for SCC H&N demonstrate excellent rates patients recurrent refractory disease. II III trials examining safety these combinations are currently underway. To date, has well-tolerated, skin rashes allergic reactions being most clinically important adverse events reported. displays dose-dependent elimination characteristics a half-life approximately 7 days. Current recommendations dosing include 400 mg/m2 loading dose, followed weekly infusions 250 mg/m2.